Method for protecting bone marrow against chemotherapeutic drugs using transforming growth factor beta 1

US5278145A · kind A · utility

Assignee

• The United States of America, as represented by the Department of Health and Human Services · US

Inventors

• Jonathan R. Keller · Frederick, US
• Francis W. Ruscetti · New Market, US
• Robert Wiltrout · Woodsboro, US

Key dates

• Filing date: Jan 7, 1992
• Grant date: Jan 11, 1994
• Expiry date: Jan 7, 2012

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K38/1841
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to a method for protecting hematopoietic stem cells from the myelotoxicity of chemotherapeutic drugs or radiation therapy, which comprises, administering to a subject a therapeutically effective amount of transforming growth factor beta 1 for protecting bone marrow from the myelotoxicity of chemotherapeutic drugs or radiation therapy. The TGF.beta.1 may be administered prior (e.g. 24 hours) to the administration of the chemotherapeutic drugs or radiation therapy. Preferably, the TGF.beta.1 is administered to the subject in an amount of about 5 .mu.g to 25 .mu.g per kg body weight. The patient or subject of the present invention may be a mammal (e.g. human, domestic animal such as horse, cow, dog, cat or pig) and is preferably a human being. The mode of administration is either by interfemoral arterial, interperitoneally or subcutaneously, and preferably is by injection.